GP1BA and COVID-19: Although spike protein binding with CD42b might promote both prothrombotic and antithrombotic effects, it appears the prothrombotic mechanisms predominate if these processes are both active in patients infected with SARS-CoV-2 given that bleeding has not been reported clinically, but patients with severe COVID-19 frequently experience thrombosis and thromboembolism.